Introduction {#s01}
============

Colorectal cancer (CRC) is the third most common malignancy in the United States, with ∼50,000 deaths each year ([@bib69]). Chronic intestinal inflammation ([@bib76]) and elevated activity of epidermal growth factor receptor (EGF-R) have been associated with increased risk of CRC ([@bib68]). CRCs arise after the loss of tumor suppressor genes, including adenomatous polyposis coli (APC), from intestinal epithelial stem cells that reside at the base of the crypt. This is followed by a stepwise accumulation of mutations in oncogenes, such as the Kirsten rat sarcoma virus oncogene *KRAS* ([@bib31]). The standard of care for unresectable metastatic CRC includes chemotherapy combined with neutralizing antibodies targeting vascular endothelial growth factor (VEGF) or EGF-R ([@bib78]). Because overexpression of EGF-R is found in the majority of CRC patients, therapeutic inhibition of this signaling cascade is a seemingly obvious treatment option ([@bib18]). However, it is now clear that EGF-R--blocking antibodies, including cetuximab or pantuximab, are beneficial only in patients who do not harbor *KRAS* mutations ([@bib39]; [@bib78]). Unfortunately, even in *KRAS* WT patients with an initial response, resistance against EGF-R blockade almost invariably occurs ([@bib54]). Therefore, new therapeutic strategies for the treatment of CRC are warranted.

The receptor tyrosine kinase EGF-R controls proliferation, differentiation, gastric barrier function, and cellular survival, highlighting a driving role in various epithelial cancers ([@bib14]; [@bib68]). EGF-R belongs to a family of four receptors ([@bib3]), which are engaged by 11 different ligands, leading to activation of several signaling pathways often involved in cell fate decisions ([@bib3]). Each of the ligands for EGF-R is synthesized as a transmembrane precursor protein, which needs to be cleaved to act systemically ([@bib8]). This cleavage is performed by members of the ADAM (a disintegrin and metalloprotease) family, with most ligands cleaved by the protease ADAM17, which is a membrane-bound metalloprotease ([@bib7]; [@bib46]). To date, more than 80 different substrates have been reported for ADAM17, including TNFα, IL-6 receptor (IL-6R), L-selectin, and both TNFα receptors ([@bib64]). As such, ADAM17 regulates the IL-6 trans-signaling pathway through generation of the soluble IL-6R (sIL-6R; [@bib83]), which drives most of the proinflammatory activities of the cytokine IL-6 ([@bib62]).

Systemic ADAM17 knockout mice are not viable ([@bib52]). For this reason, we previously generated hypomorphic ADAM17 mice by inserting an additional exon into the *ADAM17* gene ([@bib13]). The new exon starts with an in-frame stop codon that is flanked by splice donor/acceptor sites, which slightly deviate from the canonical consensus sequence. This novel strategy resulted in viable mice, called ADAM17^ex/ex^ mice, with significantly reduced ADAM17 protein levels and no detectable cleaving activity ([@bib13]). ADAM17^ex/ex^ mice have eye, hair, and skin defects resembling those in TGFα^−/−^ mice ([@bib13]). Interestingly, in ADAM17^ex/ex^ mice, milk duct formation in the female breast, which is known to be EGF-R dependent ([@bib73]), was severely compromised ([@bib13]). Furthermore, upon challenge with dextran sodium sulfate (DSS), ADAM17^ex/ex^ mice exhibited defective regeneration of the colonic epithelium, which could be overcome by administration of recombinant EGF-R ligands ([@bib13]). From these observations, we hypothesized that in ADAM17^ex/ex^ mice, EGF-R activity was largely abrogated by a lack of EGF-R ligand shedding ([@bib13]).

IL-6 is an inflammatory cytokine that plays an important role in inflammatory bowel disease ([@bib2]) and intestinal cancer ([@bib17]). On target cells, IL-6 binds to the IL-6 receptor (IL-6R), and the complex of IL-6 and IL-6R binds to the ubiquitously expressed signaling receptor subunit gp130, which upon dimerization initiates intracellular signaling via the STAT3 and ERK pathways ([@bib65]). Cells that do not express IL-6R cannot respond to IL-6 but can be stimulated by IL-6 bound to a soluble form of the IL-6R (sIL-6R). This signaling pathway, termed IL-6 trans-signaling ([@bib61]), is essential for colitis ([@bib2]) and other inflammatory diseases ([@bib26]).

In the present study, we analyzed the role of ADAM17 in the development of colon cancer using the *APC*^Min/+^ model of familial adenomatous polyposis, where a heterozygous germ line truncation in the *apc* gene results in the development of small and large intestinal tumors after the spontaneous loss of heterozygosity of the remaining *apc* WT allele ([@bib82]). We found that in the absence of ADAM17, not only was tumor formation abrogated, but also the few residual tumors detected in ADAM17^ex/ex^ mice were of low-grade dysplasia. Furthermore, we could demonstrate that tumor formation required sIL-6R--dependent IL-6 trans-signaling, since it could be inhibited with the IL-6 trans-signaling inhibitory protein sgp130Fc ([@bib27]). These results suggest that blockade of IL-6 trans-signaling may be a novel CRC therapeutic strategy that could circumvent intrinsic and acquired resistance to EGF-R blockade.

Results {#s02}
=======

Expression of EGF-R, but not ADAM17, is a prognostic factor for metastatic CRC {#s03}
------------------------------------------------------------------------------

Because EGF-R activation requires ADAM17 activity, we analyzed 361 (for ADAM17) and 330 (for EGF-R) human tissue microarray samples from patients with Union for International Cancer Control (UICC) stage II--III surgically resected CRC for EGF-R and ADAM17 expression. In Fig. S1 A, we show representative examples for both proteins expressed at various levels. Fig. S1 (B and C) depicts the highly variable distribution of EGF-R and ADAM17 expression. As reported, overall survival was significantly higher in patients with no, low, and intermediate EGF-R expression compared with patients with high EGF-R expression (Fig. S1 D). However, no significant correlation between ADAM17 expression or ADAM17-positive stained cells and overall survival was detected (Fig. S1 E). This was not completely unexpected, since ADAM17 mRNA is found in virtually all cells ([@bib64]; [@bib77]) and regulation of ADAM17 activity occurs mainly at the posttranslational level ([@bib38]; [@bib70]; [@bib16]). Our data confirm recent studies that EGF-R expression is a prognostic marker for CRC ([@bib20]; [@bib72]) with no similar prognostic value for expression of the protease ADAM17. Therefore, we turned our attention to the analysis of the biological activity of EGF-R and ADAM17.

EGF-R activation in human colon cancer cells depends on ADAM17 activity {#s04}
-----------------------------------------------------------------------

We found that all seven tested human epithelial colon adenocarcinoma cell lines expressed ADAM17 and EGF-R protein (not depicted). In HCA-7 cells, we detected only EGF-R mRNA, but no expression of other ErbB receptors ([Fig. 1 A](#fig1){ref-type="fig"}), highlighting that EGF-R is the dominant ErbB family member present. In addition, HCA-7 cells expressed the EGF-R ligands betacellulin, EGF, amphiregulin, and epiregulin but not the Erb3/4 ligand neuregulin 2 ([Fig. 1 A](#fig1){ref-type="fig"}). Interestingly, we found that EGF-R was strongly autophosphorylated in HCA-7 colon adenocarcinoma cells ([Fig. 1 B](#fig1){ref-type="fig"}) without exogenous stimulation. This was dependent on the activity of ADAM17 because the inhibition of the ADAM family member ADAM10 with GI254023 ([@bib23]) did not reduce EGF-R phosphorylation, whereas treatment with GW280264, which blocks both ADAM10 and ADAM17 activity ([@bib23]) strongly reduced EGF-R phosphorylation to the same extent as the pan-metalloprotease inhibitor marimastat or the EGF-R kinase inhibitor AG1478 ([@bib84]). As a control, stimulation of HCA-7 cells with EGF led to a further increase of EGF-R phosphorylation ([Fig. 1 B](#fig1){ref-type="fig"}).

![**EGF-R activation in CRC cells depends on ADAM17 activity. (A)** qRT-PCR analysis of members of the EGF-R family and ligands in HCA-7 cells. Two independent experiments were performed and measured in triplicate. Error bars indicate means ± SD. **(B)** Autophosphorylation of EGF-R was inhibited by ADAM17 blockade. HCA-7 cells were treated for 24 h with 0.1% DMSO, the metalloprotease inhibitors GI (GI254023X, ADAM10-selective, 3 µM) and GW (GW280264X, ADAM10- and ADAM17-selective, 3 µM), the pan-metalloprotease inhibitor Marimastat (MM; 10 µM), and the EGF-R kinase inhibitor AG1478 (10 µM). Cells stimulated with 100 ng/ml EGF served as positive control. Tyrosine-phosphorylated EGF-R and total EGF-R were assessed by Western blot analysis. The ratio of intensities of the pEGF-R and EGF-R bands is shown below the blot. One representative of four independent experiments is shown. **(C)** Amphiregulin in cellular supernatants was measured by ELISA. Cells were treated for 24 h with 0.1% DMSO, 3 µM GI254023X, 3 µM GW280264X, 10 µM Marimastat, 10 µM AG1478, or 100 ng/ml human EGF. Three independent experiments were performed, and measurements were done in triplicate. Error bars indicate means ± SD. \*\*, P = 0.0078 (GW) and P = 0.0027 (MM) by unpaired *t* test.](JEM_20171696_Fig1){#fig1}

Under basal conditions, we detected high levels of soluble amphiregulin in the supernatant of HCA-7 cells, which was not reduced upon ADAM10 inhibition but was drastically reduced when ADAM17 was inhibited or a broad-spectrum metalloprotease inhibitor was applied. Inhibition of the kinase domain of EGF-R with AG1478 had no influence on soluble amphiregulin levels, whereas EGF stimulation led to a slight increase of this EGF-R ligand in the supernatant ([Fig. 1 C](#fig1){ref-type="fig"}). We conclude from these experiments that ADAM17 activity is needed for constitutive EGF-R activation in these colon adenocarcinoma cells, and that this was most likely caused by ADAM17-mediated shedding of EGF-R ligands such as amphiregulin in a process that has been termed trans-activation ([@bib55]).

Size of small-intestine organoids from Apc^Min/+^ mice is altered by the absence of ADAM17 {#s05}
------------------------------------------------------------------------------------------

Having shown that ADAM17 activity was a prerequisite of EGF-R activation in HCA-7 human colon adenocarcinoma cells, we decided to study Apc^Min/+^ mice, which have only one functional allele of the tumor suppressor Apc. Loss of the remaining Apc WT allele leads to ligand-independent activation of the canonical Wnt signaling cascade, nuclear accumulation of β-catenin, and development of intestinal adenomas primarily in the small intestine ([@bib30]). ADAM17 protein expression was virtually undetectable in organoids derived from Apc^Min/+^::ADAM17^ex/ex^ compound mutant mice (Fig. S2 A). Single organoids from Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice were similar in spheroid shape ([Fig. 2 A](#fig2){ref-type="fig"}, left). As shown in [Fig. 2 A](#fig2){ref-type="fig"} (right), in the absence of ADAM17, expression of the proliferation marker Ki67 and the transcription factor T (brachyury), a metastatic tumor marker in colon cancer ([@bib29]), was decreased. Because organoids were cultured in the presence of EGF but in the absence of IL-6, there was no difference in detectable phosphorylated EGF-R (pEGF-R) and phosphorylated STAT3. However, there were fewer and smaller organoids from Apc^Min/+^::ADAM17^ex/ex^ mice compared with Apc^Min/+^ mice ([Fig. 2 B](#fig2){ref-type="fig"}). Expression of the Wnt target genes *c-Myc*, *Axin-2*, *Birc5*, and *Ctgf* was elevated in organoids of Apc^Min/+^ mice compared with WT mice, which was partially rescued in organoids from Apc^Min/+^::ADAM17^ex/ex^ mice, except for *Axin-2*, which showed a similar expression as in organoids derived from Apc^Min/+^ mice ([Fig. 2 C](#fig2){ref-type="fig"}). Expectedly, no *IL-6* mRNA was detected in the organoids, whereas expression of *Il-6r* mRNA was up-regulated in organoids with an Apc^Min/+^ background (Fig. S2 B). The mRNA of *Il6st* (gp130) in organoids from Apc^Min/+^ mice was up-regulated in the absence of ADAM17 (Fig. S2 B). We also found high expression of *Yap-1*, *Lats1*, and *Cyr61* in organoids from Apc^Min/+^ mice, which was not changed in the absence of ADAM17 (Fig. S2 B). In addition, we showed that shedding of amphiregulin and TNFR~I~ was strongly reduced in organoids from Apc^Min/+^::ADAM17^ex/ex^ mice ([Fig. 2 D](#fig2){ref-type="fig"}), and shedding was further inhibited by the ADAM17 inhibitor GW280264 (Fig. S2 C). Organoids from Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice grew in the absence of the Wnt signaling enhancer R-Spondin-1 and Wnt3a (not depicted). However, when cultured for two passages in the absence of EGF, organoid cultures from Apc^Min/+^::ADAM17^ex/ex^ mice yielded significantly fewer organoids than cultures from ADAM17-proficient Apc^Min/+^ mice, possibly reflecting the reduced shedding of mature amphiregulin into the culture medium and associated autocrine signaling in the absence of ADAM17 ([Fig. 2 E](#fig2){ref-type="fig"}). These results not only confirm that the Wnt pathway is activated in Apc^Min/+^ mice but also that in the absence of ADAM17, Wnt signaling was reduced alongside the capacity to form organoids.

![**Effects of ADAM17 on intestinal organoids from Apc^Min/+^ animals. (A)** Left: Bright-field images of APC^min/+^ and APC^min/+^::ADAM17^ex/ex^ intestinal organoids grown in Matrigel spots. Bars, 200 µm in both magnifications. Right: Immunofluorescent staining of intestinal organoids using the primary antibodies indicated in the figure. Top: Merged picture of all three fluorescent channels. Bottom: Magnified areas of the single fluorescent channel, marked by dotted lines in the upper panel. Bars, 50 µm. Three to six high-power-field images were recorded, and representative images are shown. **(B)** Numbers and sizes of primary organoids from Apc^Min/+^::ADAM17^ex/ex^ mice formed 10 d after isolation. Primary organoids were isolated from the small intestine of 24-wk-old Apc^Min/+^ (*n* = 6) and Apc^Min/+^::ADAM17^ex/ex^ (*n* = 9) mice. \*, P \< 0.05; \*\*\*, P \< 0.001 by Mann--Whitney test. **(C)** qRT PCR analysis of selected target genes from Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ organoids. Four independent experiments were performed. qRT-PCR was done in triplicate. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; ns, nonsignificant by unpaired *t* test with Welch's correction. **(D)** Levels of soluble proteins in the supernatant of Apc^Min/+^ organoid cultures determined by ELISA. Five independent experiments were performed. \*\*\*, P \< 0.001 by Mann--Whitney test. **(E)** Plating efficiency of Apc^Min/+^ organoids was reduced in the absence of ADAM17 activity in medium without EGF. Five independent experiments were performed. \*, P \< 0.05 by two-way ANOVA with Bonferroni post hoc test. Error bars indicate means ± SD.](JEM_20171696_Fig2){#fig2}

Tumor formation in the Apc^Min/+^ model is reduced in the absence of ADAM17 {#s06}
---------------------------------------------------------------------------

Although the intestinal architecture and cellularity of ADAM17^ex/ex^ mice was normal (not depicted), these mice were highly susceptible to DSS-induced colitis, suggesting changes to epithelial cell behavior ([@bib13]). With this in mind, we next determined the impact of ADAM17 loss on tumorigenesis in the Apc^Min/+^ model, which has previously been shown to be dependent on EGF-R activity ([@bib60]). We therefore analyzed tumor formation in Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice. Here, lack of ADAM17 resulted in almost complete abrogation of tumorigenesis compared with the high tumor load in the intestine of Apc^Min/+^ mice ([Fig. 3, A and B](#fig3){ref-type="fig"}). Interestingly, the few tumors that still occurred in Apc^Min/+^::ADAM17^ex/ex^ mice were of similar size as the tumors found in Apc^Min/+^ mice ([Fig. 3 C](#fig3){ref-type="fig"}), indicating that the ADAM17-EGF-R axis plays an important role in the tumor-initiating stage rather than in the outgrowth of the tumors. In Apc^Min/+^ mice, tumors primarily arose in the jejunum and ileum (Fig. S3). Although there was no major increase in the inflammatory infiltrate in dysplasias of both mouse strains ([Fig. 3, D and E](#fig3){ref-type="fig"}), in both Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice, we noted increased infiltration of F4/80-positive macrophages in unaffected tissues versus in dysplasias (Fig. S4 A). There was no significant difference in the infiltration of CD3-positive T cells between Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice (Fig. S4 B).

![**ADAM17 deficiency reduces intestinal tumor burden. (A)** Representative images of small intestine tissue from WT, Apc^Min/+^, and Apc^Min/+^::ADAM17^ex/ex^ mice. Bars: (top) 1,000 µm; (bottom) 2,000 µm. Arrows point to neoplasias analyzed. **(B and C)** Tumor numbers (B) and tumor sizes (C) were determined macroscopically in the small intestine. Apc^Min/+^ (*n* = 15) and Apc^Min/+^::ADAM17^ex/ex^ (*n* = 14) mice were analyzed at 6 mo. \*\*, P \< 0.01 by Mann--Whitney test. **(D)** Grading of inflammatory infiltrate in dysplasia from Apc^Min/+^ mice and hypomorphic Apc^Min/+^::ADAM17^ex/ex^ mice. Inflammatory scoring (0, no infiltrate; 1, mild infiltrate; 2, moderate infiltrate; 3, severe infiltrate). Apc^Min/+^ (*n* = 10) and Apc^Min/+^::ADAM17^ex/ex^ (*n* = 8) mice. ns, nonsignificant by unpaired *t* test. **(E)** Representative H&E images of small intestines of Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice. Bars: (panels) 100 µm; (insets) 50 µm. Error bars indicate means ± SD.](JEM_20171696_Fig3){#fig3}

Representative H&E-stained tissue from Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice ([Fig. 4 A](#fig4){ref-type="fig"}) indicated that Apc^Min/+^ mice developed low-grade dysplasias, high-grade dysplasias, and carcinomas, as has been described previously ([@bib43]). In contrast, in Apc^Min/+^::ADAM17^ex/ex^ mice, only low-grade dysplasias were detected ([Fig. 4, A and B](#fig4){ref-type="fig"}), indicating that in the absence of ADAM17, tumors do not progress beyond this stage. The rather benign status of dysplasia in Apc^Min/+^::ADAM17^ex/ex^ mice is underlined by strongly reduced nuclear β-catenin staining ([Fig. 5 A](#fig5){ref-type="fig"}), reduced proliferation as assessed by Ki67 staining ([Fig. 5 B](#fig5){ref-type="fig"}), and strongly reduced nuclear STAT3 staining ([Fig. 5 C](#fig5){ref-type="fig"}), reflecting reduced STAT3 activation in the absence of ADAM17. These data underline the important role of ADAM17 in not only tumor initiation but also the grade of dysplasia and invasive behavior of tumors.

![**Staging of dysplasias in Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice. (A)** Representative images of H&E-stained tissue of Apc^Min/+^ mice and Apc^Min/+^::ADAM17^ex/ex^ mice. **(B)** Staging of dysplasia from Apc^Min/+^ mice and Apc^Min/+^::ADAM17^ex/ex^ mice. Numbers of low-grade dysplasias, high-grade dysplasias, and carcinomas from Apc^Min/+^ (*n* = 10) and Apc^Min/+^::ADAM17^ex/ex^ (*n* = 8) mice at 6 mo. \*\*, P \< 0.01 by Mann--Whitney test. Error bars indicate means ± SD.](JEM_20171696_Fig4){#fig4}

![**Decreased β-catenin, Ki67, and nuclear STAT3 staining in Apc^Min/+^::ADAM17^ex/ex^ mice. (A--C)** Representative images of tissue from Apc^Min/+^ mice and Apc^Min/+^::ADAM17^ex/ex^ mice stained for β-catenin (A), Ki-67 (B), and STAT3 (C). Small intestine from 24-wk-old Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice was used for IHC analysis to visualize β-catenin, Ki-67 and STAT3. Apc^Min/+^ (*n* = 8) and Apc^Min/+^::ADAM17^ex/ex^ (*n* = 6) mice. Bars: (panels) 50 µm; (insets) 20 µm.](JEM_20171696_Fig5){#fig5}

Our data suggested that ADAM17-mediated shedding of EGF-R ligands is needed for EGF-R activation in tumor development. Recently, it was shown in an inflammation-associated cancer model ([@bib20]; [@bib72]), as well as in the Apc^Min/+^ model ([@bib72]), that genetic deletion of the *egfr* gene in intestinal epithelial cells did not result in reduced tumorigenesis, whereas *egfr* deletion in myeloid cells led to a drastic reduction in tumor numbers. It was further shown that EGF-R activation on tumor-infiltrating macrophages led to the secretion of IL-6, which stimulated tumor growth on intestinal epithelial cells ([@bib72]). In line with these findings, we failed to detect significant differences in EGF-R phosphorylation in intestinal sections of Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice (not depicted). We therefore sought to analyze gene expression patterns in tissues and tumors of Apc^Min/+^ mice in the absence or presence of ADAM17 activity to understand the signaling pathways involved in colon cancer formation.

Gene expression analysis of dysplasia from Apc^Min/+^ mice in the presence and absence of ADAM17 {#s07}
------------------------------------------------------------------------------------------------

To further delineate the molecular mechanism underpinning the effect of ADAM17 on tumor formation, we obtained epithelial mucosa from both tumor and nontumor compartments of Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice by laser capture microdissection. In comparison to healthy tissue from WT animals, tumors from Apc^Min/+^ mice showed high expression of EGF-R and amphiregulin, which was reduced in the absence of ADAM17 ([Fig. 6 A](#fig6){ref-type="fig"}). Similar to the situation in organoids ([Fig. 2](#fig2){ref-type="fig"}), we also found elevated expression of Wnt target genes and up-regulation of *Il-6*, *Il-6r*, and *birc5* mRNA in tumors from Apc^Min/+^ mice, which were mostly down-regulated in the absence of ADAM17 ([Fig. 6 B](#fig6){ref-type="fig"}). Given that IL-6 via STAT3 activation plays a pivotal role in intestinal tumorigenesis ([@bib17]), we analyzed the expression of the STAT3 target gene *birc5*, also known as *survivin*. The expression of *birc5* was down-regulated in Apc^Min/+^::ADAM17^ex/ex^ mice, whereas *sox-9* and *Il-6r* mRNA was more highly expressed in Apc^Min/+^::ADAM17^ex/ex^ mice. In addition, *yap-1*, *ctgf*, and *cyr61* mRNAs were lower in tissue from Apc^Min/+^::ADAM17^ex/ex^ mice compared with Apc^Min/+^ mice ([Fig. 6 B](#fig6){ref-type="fig"}).

![**Changes in gene expression in Apc^Min/+^::ADAM17^ex/ex^ mice. (A)** Laser microdissection and qRT-PCR analysis of ErbB family receptors and ligands from dysplasia of Apc^Min/+^ mice and Apc^Min/+^::ADAM17^ex/ex^ mice. Tissue samples from six dysplasias from Apc^Min/+^ mice (*n* = 3) and four dysplasias from Apc^Min/+^::ADAM17^ex/ex^ mice (*n* = 2) were collected via laser microdissection and compared with WT tissue. qRT-PCR analysis was performed in triplicate. \*\*\*, P \< 0.001 by two-way ANOVA with Bonferroni post hoc test. **(B)** qRT-PCR analysis of selected target genes from Apc^Min/+^ mice and Apc^Min/+^::ADAM17^ex/ex^ mouse tissue. 26 tumor samples obtained from Apc^Min/+^ mice (*n* = 7) and 10 tumor samples obtained from Apc^Min/+^::ADAM17^ex/ex^ mice (*n* = 4) were compared with tissue samples from WT mice (*n* = 1). \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; ns, nonsignificant by unpaired *t* test with Welch's correction. Error bars indicate means ± SD.](JEM_20171696_Fig6){#fig6}

To obtain a more comprehensive view of transcriptome alterations that were associated with a lack of ADAM17, we performed RNA sequencing (RNA-seq) from nontumor and tumor tissue isolated from Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice. 3196 genes were up-regulated and 2883 genes were down-regulated in tumors of Apc^Min/+^ mice versus Apc^Min/+^ADAM17^ex/ex^ mice. In nontumor intestinal tissue, 90 genes were up-regulated and 58 genes were down-regulated in Apc^Min/+^ mice versus Apc^Min/+^::ADAM17^ex/ex^ mice. Principal component analysis showed only a partial separation of tumor and normal tissue by genotype ([Fig. 7 A](#fig7){ref-type="fig"}). The top 100 genes that were differentially expressed in Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice are depicted in [Fig. 7 B](#fig7){ref-type="fig"}, demonstrating a distinct gene expression signature in both mouse strains. The cluster of transcripts up-regulated in the Apc^Min/+^ tumors contained several transcripts that have been previously related to CRC (e.g., T \[brachyury\], IL11, GATA4, JAG2; [@bib22]; [@bib29]; [@bib11]; [@bib80]). A STRING-based network analysis of the top 500 regulated transcripts confirmed this observation and showed densely connected subnetworks up-regulated in the Apc^Min/+^ versus Apc^Min/+^::ADAM17^ex/ex^ tumors around Wnt signaling and cytokine/chemokine signaling (not depicted). Thus we analyzed conserved transcription factor binding sites (TFBSs) using the oPossum tool ([@bib35]) to identify enriched motifs using the full set of regulated transcripts. The analysis indicated an overrepresentation of genes regulated by transcription factors such as KLF4, SP1, and Zfx, which have been associated with cellular proliferation and stemness in Apc^Min/+^ tumors, which is down-regulated in the absence of ADAM17 ([Fig. 7 C](#fig7){ref-type="fig"}). Most interestingly, in tumor tissue, TCFCP2L1, a known Wnt target ([@bib56]), and STAT3 TFBSs were enriched with high statistical scores (*z*-score and Fisher score). We next tested for known Wnt and STAT3 target genes (<https://web.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes>; [@bib53]) and found several of them significantly more highly expressed in Apc^Min/+^ mice compared with Apc^Min/+^::ADAM17^ex/ex^ mice ([Table 1](#tbl1){ref-type="table"}), again indicating that the IL-6-gp130-STAT3 axis was involved in intestinal tumorigenesis. Higher expression of T (brachyury) and SAA1 in the intestine of Apc^Min/+^ mice compared with Apc^Min/+^::ADAM17^ex/ex^ mice was confirmed by immunohistochemistry (IHC; not depicted). In contrast, expression of amphiregulin protein was higher in the intestine of Apc^Min/+^::ADAM17^ex/ex^ mice, presumably because of the absence of ADAM17 shedding activity (not depicted), as has already been demonstrated for the EGF-R ligand TGFα, which accumulated at the cell surface of intestinal epithelial cells in the absence of ADAM17 ([@bib13]). A network analysis (based on STRING database) depicting the interaction matrix of up-regulated transcripts from unaffected tissue from Apc^Min/+^ mice compared with Apc^Min/+^::ADAM17^ex/ex^ mice (corrected P \< 0.01, no additional white nodes) revealed two larger modules around epithelial differentiation (e.g., keratins KRT7, 12 and 14, serpin B5, Muc5ac) and cell adhesion/cytoskeleton (e.g., integrin β6, laminin gamma 2 and β-actin). The network modules are depicted in [Fig. 7 D](#fig7){ref-type="fig"}.

![**RNA-seq analysis of tumors and unaffected tissue from Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice. (A)** Principal component analysis (PCA) of mRNA expression levels. The plot depicts the first two components, which explain the major part of the variation. Individual samples are color- and symbol-coded by tissue type (tumor and normal colonic tissue) and genotype (Apc^Min/+^ vs. Apc^Min/+^::ADAM17^ex/ex^). We compared four nontumor tissue samples from Apc^Min/+^ mice (*n* = 3) and six nontumor tissue from Apc^Min/+^::ADAM17^ex/ex^ mice (*n* = 3) with 12 tumor tissue samples from Apc^Min/+^ mice (*n* = 3) and 17 tumor tissue samples from Apc^Min/+^::ADAM17^ex/ex^ mice (*n* = 4) as described in Materials and methods. **(B)** Hierarchical clustering of the top 100 (ranked by *p*-value) genes differentially expressed in tumor tissue from Apc^Min/+^ versus Apc^Min/+^::ADAM17^ex/ex^ mice as described in Materials and methods. **(C)** Transcription factor binding inference using up-regulated gene sets from normal tissue and tumors. The table depicts enriched conserved TFBSs in the Apc^Min/+^ tissue compared with Apc^Min/+^::ADAM17^ex/ex^ samples, using a fold change cutoff of \>2-fold. Analysis was performed using the oPossum3 tool. *z*-score and Fisher test score (FS) represent two independent measures to determine the TFBS motifs that are overrepresented in the respective gene set against background. **(D)** STRING network depiction of transcripts up-regulated in unaffected Apc^Min/+^::ADAM17^wt/wt^ small intestinal tissue versus tissue derived from Apc^Min/+^::ADAM17^ex/ex^ mice. The network was constructed using default parameters without allowance of first-line interactors and/or additional white nodes.](JEM_20171696_Fig7){#fig7}

###### Regulation of known Wnt and STAT3 target transcripts (RNA-seq)

  Target                                           Log2 fold change   Adjusted P-value   Increased in Apc^Min/+^ normal mucosa
  ------------------------------------------------ ------------------ ------------------ ---------------------------------------
  **Wnt signature in Apc^Min/+^ tumor tissue**                                           
  N-myc                                            1.2                8.51 × 10^--6^     No
  Axin2                                            1.1                7.13 × 10^--5^     No
  Mmp7                                             1.7                3.67 × 10^--5^     No
  Wnt5a                                            1.4                7.54 × 10^--13^    No
  Wnt7a                                            2.4                0.000181284        No
  Efnb2                                            0.7                0.011594455        No
  Efna2                                            0.9                0.012058086        No
  Fgf18                                            1.8                0.00117603         No
  Sox9                                             2.2                3.12 × 10^--11^    No
  Sox2                                             1.5                0.037838719        No
  T                                                4.7                2.44 × 10^--16^    No
  Tbx1                                             2.8                4.02 × 10^--10^    No
  Tbx4                                             2.3                9.17 × 10^--6^     No
  Ccdn1                                            0.8                3.89 × 10^--6^     No
  **Stat3 signature in Apc^Min/+^ tumor tissue**                                         
  Reg3b                                            1.5                0.002154754        No
  Reg4                                             1.7                0.000230609        No
  Areg                                             1.9                5.16 × 10^--7^     No
  Lrg1                                             3.5                1.96 × 10^--15^    No
  Trf                                              1.3                0.000473624        No
  Pla2g2f                                          3.5                1.58 × 10^--14^    No
  Fut9                                             1.6                0.022056147        No
  Saa1                                             1.6                0.011289854        No
  Saa3                                             2.8                4.88 × 10^--12^    No
  Socs3                                            0.6                2.05 × 10^--6^     Yes
  Ncald                                            0.8                0.005328861        No
  Duox2                                            2.1                4.35 × 10^--7^     No
  Duoxa2                                           2.5                1.68 × 10^--7^     Yes

Influence of ADAM17 on the intestinal microflora {#s08}
------------------------------------------------

The intestinal microbiome strongly affects barrier function and tumor formation ([@bib50]). Because ADAM17 is needed for proper intestinal barrier function ([@bib13]), we wondered whether the absence of ADAM17 would have an influence on the composition of the intestinal microbiome. We profiled the fecal microbiome from unchallenged WT and ADAM17^ex/ex^ mice by analyzing the DNA sequence encoding the 16S rRNA. Multidimensional scaling revealed distinct clustering between WT, heterozygous ADAM17^wt/ex^, and homozygous ADAM17^ex/ex^ mice (Fig. S5 A). Significant changes were observed by operational taxonomical unit analysis of the respective genotypes depicted by heat map (Fig. S5 B). Interestingly, several bacterial taxa were depleted in the hypomorphic ADAM17^ex/ex^ animals, which are involved in fermentation of dietary fiber into butyrate (*Coprococcus*, *Ruminococcus*; Fig. S5 B), a metabolic process protecting from colonic inflammation and carcinogenesis ([@bib10]). Similar shifts in abundances have been detected in human CRC patients. Altogether, these data indicate that without any additional stimulus or pathological condition, the absence of ADAM17 has a remarkable effect on constitution of the intestinal microbiota, which might relate to the altered epithelial gene expression and contribute to tumorigenesis. Moreover, as shown in Fig. S5 C, inferred Kyoto Encyclopedia of Genes and Genomes (KEGG) categories in [d]{.smallcaps}-arginine, [d]{.smallcaps}-ornithine metabolism and inositol phosphate metabolism were significantly different between WT and ADAM17^ex/ex^ mice. These metabolites are considered to be important for the maintenance of intestinal barrier function ([@bib15]).

Tumor formation in the Apc^Min/+^ model is dependent on IL-6 trans-signaling {#s09}
----------------------------------------------------------------------------

EGF-R activity in myeloid cells is needed for tumorigenesis in the Apc^Min/+^ model ([@bib72]) as well as in an inflammation-associated CRC model ([@bib20]; [@bib72]). Because the sIL-6R is generated via limited proteolysis by the ADAM17 protease ([@bib83]), and IL-6 expression in colonic myeloid CD11b-positive cells depends on the presence of the EGF-R ([@bib72]), we decided to analyze a possible role of the IL-6 trans-signaling pathway in tumorigenesis. This hypothesis was supported by our gene expression data, which showed that in Apc^Min/+^ mice, Wnt and STAT3 regulated genes were significantly down-regulated in the absence of ADAM17 ([Table 1](#tbl1){ref-type="table"}). Furthermore, it has recently been shown that IL-6 is involved in the homeostasis of intestinal crypts ([@bib1]; [@bib24]) and that tumor formation in the Apc^Min/+^ model was reduced on an IL-6^−/−^ genetic background ([@bib4]).

IL-6 trans-signaling can be specifically blocked by a soluble form of gp130 dimerized via a human IgG1 Fc (sgp130Fc) without affecting classic IL-6 signaling via the membrane-bound IL-6R ([@bib27]). We previously generated transgenic mice (sgp130Fc-tg mice) that expressed the sgp130Fc protein under the transcriptional control of a liver-specific promoter ([@bib57]). These mice were shown to be completely resistant to IL-6 trans-signaling--mediated pathologies ([@bib37]; [@bib34]; [@bib6]). We therefore compared tumor formation in Apc^Min/+^, Apc^Min/+^::IL-6^−/−^, and Apc^Min/+^::sgp130Fc-tg mice. There was no significant difference in the onset of tumor formation at 100 d ([Fig. 8, A and B](#fig8){ref-type="fig"}), as indicated by both tumor number and tumor size. However, as tumors progressed to 150 and 200 d, Apc^Min/+^ mice on the IL-6^−/−^ and sgp130Fc-tg genetic background showed similarly reduced tumor numbers and tumor areas. Although tumor numbers were initially lower in the absence of IL-6 classic and trans-signaling on the IL-6^−/−^ genetic background ([Fig. 8, C and D](#fig8){ref-type="fig"}), after 200 and 300 d ([Fig. 8, E--H](#fig8){ref-type="fig"}), a time point when few Apc^Min/+^ mice were still alive, Apc^Min/+^::IL-6^−/−^ and Apc^Min/+^::sgp130Fc-tg mice showed strongly reduced tumor numbers and tumor sizes, indicating that IL-6 via the IL-6 trans-signaling pathway was involved in the later stages of Apc^Min/+^ tumorigenesis. IHC analysis ([Fig. 8 I](#fig8){ref-type="fig"}) revealed a tendency to more intensive staining for pSTAT3 and pEGF-R in tumors compared with unaffected tissues. Tumors of Apc^Min/+^ mice exhibited more pEGF-R reactivity than Apc^Min/+^::IL-6^−/−^ and Apc^Min/+^::sgp130Fc-tg mice. In agreement with the experimental data shown in Fig. S4, there was no clear difference in infiltrating CD3-positive T cells ([Fig. 8 I](#fig8){ref-type="fig"}) and F4/80 macrophages (not depicted) in tumors of Apc^Min/+^, Apc^Min/+^::IL-6^−/−^ and Apc^Min/+^::sgp130Fc-tg mice. Collectively, our data indicate that tumor formation in the Apc^Min/+^ model relies on IL-6 activity via the sIL-6R.

![**Tumor number and tumor area of Apc^Min/+^ mice depends on IL-6 trans-signaling via the sIL-6R. (A--H)** Tumor number (A, C, E, and G) and tumor area (B, D, F, and H) of Apc^Min/+^ mice on WT, IL-6^−/−^, and sgp130Fc transgenic background was determined after 100 d; Apc^Min/+^, (*n* = 6); Apc^Min/+^::IL-6^−/−^, (*n* = 5); Apc^Min/+^::sgp130Fc, (*n* = 23; A, B) 150 d; Apc^Min/+^, (*n* = 4); Apc^Min/+^::IL-6^−/−^, (*n* = 10); Apc^Min/+^::sgp130Fc, (*n* = 18; C, D), 200 d; Apc^Min/+^, (*n* = 4); Apc^Min/+^::IL-6^−/−^, (*n* = 3); Apc^Min/+^::sgp130Fc, (*n* = 22; E, F) and 300 d; Apc^Min/+^, (*n* = 2); Apc^Min/+^::IL-6^−/−^, (*n* = 3); Apc^Min/+^::sgp130Fc, (*n* = 4; G, H). Error bars indicate mean ± SEM. **(I)** Representative H&E images of tissue from Apc^Min/+^, Apc^Min/+^::IL-6^−/−^ mice and Apc^Min/+^::sgp130Fc mice at 150 d of age stained for pSTAT3, pEGF-R, and CD3. Bars, 100 µm. \*\*, P \< 0.01; \*\*\*\*, P \< 0.0001.](JEM_20171696_Fig8){#fig8}

To extend a role for IL-6 trans-signaling to a preclinical setting that is more relevant for human CRC, we challenged WT mice with the alkylating mutagen azoxymethane (AOM). This treatment regimen replicated sporadic human CRC by reproducibly inducing tubular adenomas in the colon of mice in the absence of chronic inflammation conferred to by DSS or other mucosal irritants ([@bib48]). As shown in [Fig. 9 A](#fig9){ref-type="fig"}, we administered AOM to WT and sgp130Fc transgenic mice once a week for six consecutive weeks and analyzed tumor formation after 20 wk. The AOM treated sgp130Fc transgenic mice expressed sgp130Fc protein in the circulation ([@bib57]) at 2--6 µg/ml (not depicted). Tumors were visible upon endoscopy performed after 11 wk ([Fig. 9 B](#fig9){ref-type="fig"}). Protruding lesions visible upon endoscopy scored after 8, 11, and 17 wk revealed increasing numbers in WT mice, whereas significantly lower and nonincreasing numbers of lesions were found in sgp130Fc transgenic mice ([Fig. 9 C](#fig9){ref-type="fig"}). After 20 wk, the colons of WT mice exhibited several large tumors, whereas only a few small lesions were found in sgp130Fc transgenic mice ([Fig. 9, D and E](#fig9){ref-type="fig"}). Representative IHC stainings and quantifications of pSTAT3, pEGF-R, and CD3 are shown in [Fig. 9 F](#fig9){ref-type="fig"}. In agreement with the data from the APC^min/+^ model shown in [Fig. 8](#fig8){ref-type="fig"}, there were no significant differences in pSTAT3, pEGF-R, and CD3 staining between the mice in the absence or presence of IL-6 signaling. These experiments revealed that sgp130Fc mice were extensively protected from AOM-induced intestinal tumor formation and therefore confirm and extend our findings obtained in the small intestine of a model for genetic susceptibility in familial adenomatous polyposis (i.e., Apc^Min/+^ mice) to a model of colon tumorigenesis arising from the sporadic acquisition of driver mutations that underpins the majority of CRCs in humans.

![**Role of IL-6 trans-signaling in the sporadic AOM-induced tumor model. (A)** Schematic representation of the sporadic CRC model. WT or sgp130 transgenic mice were injected i.p. with AOM (10 mg/kg) once a week for a total of 6 wk. The spontaneous formation of distal colonic tumors was monitored by endoscopy once every week after 6 wk of AOM treatment. **(B)** Representative endoscopy images of distal colonic tumors (arrowhead) from WT or sgp130Fc transgenic mice at 11 wk. Bars, 2 mm at the plane of the head of the endoscope. **(C)** Representative number of protruding lesions from WT or sgp130Fc transgenic mice scored by endoscopy at 8, 11, and 17 wk. Data presented as mean ± SEM using *n* ≥ 6 mice per cohort. \*, P \< 0.05; \*\*, P \< 0.01; by Student's *t* test. **(D)** Photomicrographs of representative colons of mice of the indicated genotypes. Tumors are indicated by arrows. Bars, 1 cm. **(E)** Total tumor burden of WT or sgp130Fc transgenic mice at 20 wk. Data presented as mean ± SEM using *n* ≥ 8 mice per cohort. \*, P \< 0.05 by Student's *t* test. **(F)** Representative IHC staining and quantification for pSTAT3, pEGFR, and CD3 from WT and sgp130Fc transgenic mice. Bars, 100 µm. Data presented as mean ± SEM and analyzed by Student's *t* test.](JEM_20171696_Fig9){#fig9}

Discussion {#s10}
==========

To date, treatment of CRCs with neutralizing EGF-R antibodies is hampered by the rapid development of resistance caused by mutations within the EGF-R signaling pathway and extrinsic and intrinsic resistance mechanisms. Here we show that in vitro and in vivo, EGF-R activation requires ADAM17 activity, which acts via shedding of membrane-bound EGF-R ligands. Furthermore, we show that tumorigenesis in the Apc^Min/+^ model, which is known to require EGF-R activation ([@bib60]), is largely suppressed in the absence of ADAM17. Interestingly, this is not a result of reduced tumor progression, since the few tumors seen in Apc^Min/+^::ADAM17^ex/ex^ mice are of the same mean size as those seen in Apc^Min/+^ control mice. Moreover, in the absence of ADAM17, the detected tumors were classified as low-grade dysplasias, whereas in the presence of ADAM17, high-grade dysplasias and carcinomas were also detected. Based on the recent finding that EGF-R on myeloid cells rather than on intestinal epithelial cells is required for tumor formation in the AOM/DSS ([@bib20]; [@bib72]) and Apc^Min/+^ ([@bib72]) models, we demonstrate in two different intestinal tumor models a link between EGF-R, ADAM17, and IL-6, indicating that IL-6 trans-signaling is needed for efficient tumor formation in the intestine.

The ADAM17^ex/ex^ mouse, with its massive reduction of ADAM17 protein levels in all tissues ([@bib13]), has been used successfully to study the role of ADAM17 in various in vivo models including kidney fibrosis ([@bib28]), atherosclerosis ([@bib49]), and small vessel disease ([@bib12]). With its residual ADAM17 activity, the ADAM17^ex/ex^ mouse can serve as a model for the consequences of pharmacological inhibition of ADAM17, which will not lead to complete blockade of enzymatic activity. It has been shown that in ADAM17^ex/ex^ mice, intestinal barrier function is compromised upon challenge ([@bib13]). In the present study, we also demonstrate that, even without a challenge, the microbiome of ADAM17^ex/ex^ mice is significantly changed compared with WT mice, indicating that by affecting the abundance of butyrate-producing bacterial taxa, ADAM17 may contribute to intestinal barrier function.

IL-6 plays a dual role in intestinal homeostasis. On the one hand, in the absence of IL-6, inflammation upon challenge with DSS is more severe because of compromised regeneration ([@bib17]). This is likely caused by reduced IL-6--stimulated STAT3 activation in response to the irritant ([@bib17]). Therefore, IL-6 is important for intestinal regeneration ([@bib1]; [@bib24]), and recombinant IL-6 improved colitis in a mouse model ([@bib71]; [@bib72]). On the other hand, IL-6 via IL-6 trans-signaling drives the inflammatory response in colitis, and sgp130Fc was sufficient to efficiently block inflammation in several colitis models ([@bib2]; [@bib44]). Furthermore, it was shown in two different inflammation-associated colon cancer models that blockade of IL-6 trans-signaling resulted in significant inhibition of tumor growth ([@bib5]; [@bib41]).

One important activity of ADAM17 is shedding of the IL-6R, which is a prerequisite of IL-6 trans-signaling ([@bib59]). It was surprising that blockade of IL-6 trans-signaling was sufficient for inhibition of tumor formation in the Apc^Min/+^ model. IL-6 deficiency led to a decreased tumor load in this model ([@bib4]), and we showed in the present study that IL-6 mRNA was massively up-regulated in Apc^Min/+^ mice and down-regulated in the absence of ADAM17. Because blocking IL-6 trans-signaling was sufficient to strongly reduce tumor formation, these results now help to explain the unexpected observation that EGF-R on myeloid cells but not on intestinal epithelial cells was needed for tumor formation ([@bib20]; [@bib72]). This notion is also supported by a recent study of mice with epithelial-specific ADAM17 deletion. In these mice, AOM treatment led only to a slight reduction of adenomas and cancer compared with the dramatic reduction in tumor incidence upon blockade of IL-6 trans-signaling ([@bib47]). EGF-R stimulation on myeloid cells leads to IL-6 secretion ([@bib72]), and ADAM17 is needed for the cleavage of ligands of EGF-R such as amphiregulin. At the same time, ADAM17 is needed for shedding of the IL-6R from macrophages ([@bib66]; [@bib83]). Therefore, IL-6 induction and sIL-6R generation are both induced by ADAM17 activity, leading to stimulation of the intestinal epithelial cells via IL-6 trans-signaling.

Frequent somatic activating mutations in gp130 have been detected in inflammatory hepatocellular adenomas ([@bib58]). When such activated gp130 was expressed as a transgene in intestinal epithelial cells, proliferation and aberrant differentiation of these cells was observed, which depended on the activity of the transcriptional coactivator Yap ([@bib74]). When these transgenic mice were crossed with Apc^Min/+^ mice, the animals developed very high tumor numbers in the jejunum and ileum. Tumor incidence was dramatically reduced in the absence of STAT3 and Yap, indicating that gp130 activation is crucial for tumor development in the Apc^Min/+^ model ([@bib75]).

The important role of myeloid EGF-R activation in intestinal tumorigenesis, at least in mice, was unexpected ([@bib20]; [@bib72]), although it was known that both M1 and M2 macrophages are activated by EGF-R stimulation ([@bib19]). M1 macrophages are thought to be proinflammatory and antitumorigenic, whereas M2 macrophages are believed to act in a regenerative and protumorigenic fashion ([@bib19]). Interestingly, differentiation of M2 macrophages requires IL-6 signaling via the membrane-bound IL-6R ([@bib42]), pointing to a plausible link between EGF-R and IL-6 in the intestine.

In patients with unresectable metastatic colon cancer, besides chemotherapy, EGF-R blockade by the neutralizing antibodies cetuximab and pantuximab is applied. In the investigated and analyzed patient cohorts of the present study, cetuximab was rarely administered, and then only in the context of combinatorial treatment protocols. Thus, statistical analyses of treatment response related to ADAM17 expression was renounced because of underpower and hardly objectifiable response rates according to the Response Evaluation Criteria in Solid Tumors (RECIST) after multisubstance treatments.

The majority of patients, which can account for up to 90%, show intrinsic resistance against anti--EGF-R antibodies as a result of KRAS mutations or mutations in other signaling pathways, such as BRAF or PIK3CA, which all lie downstream of the EGF-R ([@bib81]). But even patients who respond to anti--EGF-R antibodies benefit from the treatment for only 3--12 mo because of acquired resistance mechanisms, which include mutations in the EGF-R precluding binding of cetuximab or amplification of the gene coding for the ErbB family member HER2 ([@bib81]).

In this light, it is provocative that, although depending on EGF-R activity, colon cancer seems to require IL-6 trans-signaling. As we have shown, EGF-R stimulation of CD11b-positive colonic myeloid cells led to massive IL-6 induction ([@bib72]), and sIL-6R is generated by these cells ([@bib79]). We showed in pancreatic cancer that IL-6 trans-signaling, in addition to oncogenic *KRAS*, is required for progression to ductal adenocarcinoma, and this progression was completely blocked in sgp130Fc transgenic mice ([@bib37]). The reduction in tumor load seen after blocking IL-6 signaling was less pronounced than the effect in ADAM17-deficient mice. Furthermore, it still needs to be determined whether a similar mechanism also operates in humans. Nevertheless, blocking IL-6 trans-signaling might be a new therapeutic strategy for the treatment of colon cancer that would not be affected by intrinsic or acquired resistance to EGF-R blockade.

Materials and methods {#s11}
=====================

Mice {#s12}
----

All mice were kept under barrier conditions in individually ventilated cages with species-appropriate husbandry in a 12-h light-dark cycle under standard conditions. All experiments involving mice were authorized by national law upon review of project proposals. C57BL/6J-Apc^Min/+^/J mice were purchased from Jackson Laboratory (\#002020) and were crossbred with IL-6^−/−^, sgp130Fc transgenic mice or homozygous hypomorphic ADAM17^ex/ex^ mice on a mixed C57BL/6::129 background. Generation of ADAM17 hypomorphic ADAM17^ex/ex^ mice and sgp130Fc transgenic mice was previously described ([@bib57]; [@bib13]).

Protein extraction {#s13}
------------------

To extract proteins, cells were resuspended in ice-cold lysis buffer (50 mM Tris, 150 mM NaCl, 2 mM EDTA, 1% \[vol/vol\] NP-40, 1% \[vol/vol\] Triton X-100, and two complete-protease inhibitor cocktail tablets \[Roche\] per 50 ml). Animal tissues were mechanically disrupted by using the Precellys (Peqlab) homogenizer according to the supplier's instructions. The tissue was mixed with lysis buffer (50 mM Tris, 150 mM NaCl, 0.1% \[vol/vol\] SDS, 1% \[vol/vol\] Triton X-100, and 0.5% \[wt/vol\] sodium deoxycholate) and ceramic beads for homogenization. After homogenization, samples were incubated on ice for 60 min and centrifuged at 13,000 *g* for 15 min to collect the protein-containing supernatant. Protein concentrations were determined by BCA protein assay (Pierce; Thermo Fisher Scientific). To enrich glycosylated proteins, concanavalin A precipitation was performed. After incubation at 4°C overnight, the sample was centrifuged at 5,000 *g* and washed with ice-cold PBS.

Western blotting {#s14}
----------------

Proteins in Laemmli buffer were boiled, centrifuged, and analyzed by discontinuous SDS-PAGE. Proteins were transferred onto PVDF membranes (Thermo Fisher Scientific) and blocked in 6% (wt/vol) dry nonfat milk. PVDF membranes were washed before adding the primary antibody and secondary antibody. Immunoreactive proteins were visualized by chemiluminescence.

Antibodies {#s15}
----------

Primary antibodies used for Western blot analysis were as follows: α-human ADAM17 (3976; Cell Signaling Technology); α-human EGF-R (4267; Cell Signaling Technology); and α-human pEGF-R (3777, Cell Signaling Technology). HRP-labeled secondary antibody for Western blot analysis was α-rabbit-IgG-POD (Dianova). Primary antibodies used for IHC were α-Ki-67 (12202, Cell Signaling Technology); α-β-catenin (610154, BD); α-human-STAT3 (sc-7179, Santa Cruz Biotechnology); α-p-STAT3 (sc-7993, Santa Cruz Biotechnology; 9145 Cell Signaling Technology); α-pEGF-R (GTX61353, 1:100; Genetex); and α-T (brachyury; AF2085; R&D Systems). Fluorochrome-conjugated secondary antibodies for IHC were α-rabbit-Cy3 (Dianova) and α-rabbit-FITC (Dianova).

Quantitative real-time PCR (qRT-PCR) {#s16}
------------------------------------

TRIzol reagent (Life Technologies; Thermo Fisher Scientific) was used to isolate RNA from animal tissue for cDNA synthesis and qRT-PCR according to the manufacturer's instructions. RNA from organoids was extracted using innuPREP RNA kit from Analytik Jena. RNA concentration and purity were spectrophotometrically analyzed by NanoDrop2000 (Thermo Fisher Scientific). For gene expression analysis, 1 µg RNA was reverse-transcribed by RevertAid H Minus Reverse transcription (Thermo Fisher Scientific). The cDNA was used as a template in a qRT-PCR assay on a LightCycler 480 system (Roche). All reagents were purchased from Roche. Primers were designed by using Roche Universal ProbeLibrary Assay Design Center. Primers and \#UPL-Probes were as follows: mEGF-R_up\_\#10, 5′-TGTGCAAAGGAATTACGACCT-3′; mEGF-R_dn\_\#10, 5′-GTTGAGGGCAATGAGGACA-3′; mErbB2_up\_\#25, 5′-TTTGCCGGAGAGCTTTGAT-3′; mErbB2_dn\_\#25, 5′-TCTGGCCATGCTGAAATGTA-3′; mErbB3_up\_\#99, 5′-AAGTACAACCGGCCTCTGG-3′; mErbB3_dn\_\#99, 5′-CGACAAGACAAGCACTGACC-3′; mBTC_up\_\#68, 5′-CGGGTAGCAGTGTCAGCTC-3′; mBTC_dn\_\#68, 5′-ACAGTGGAGAATTGCAAGACC-3′; mAREG_up\_\#53, 5′-TCCAAGATTGCAGTAGTAGCTGTC-3′; mAREG_dn\_\#53, 5′-CCCTGAAGTATCGTTTCCAAAG-3′; mSox9_up\_\#25, 5′-CAGCAAGACTCTGGGCAAG-3′; mSox9_dn\_\#25, 5′-ATCGGGGTGGTCTTTCTTGT-3′; mIL-6_up\_\#6, 5′-GCTACCAAACTGGATATAATCAGGA-3′; mIL-6_dn\_\#6, 5′-CCAGGTAGCTATGGTACTCCAGAA-3′; mIL6R_dn\_\#53, 5′-ATCCTCTGGAACCCCACAC-3′; mIL6R_up\_\#53, 5′-GAACTTTCGTACTGATCCTCGTG-3′; mIL6ST_up\_\#85, 5′-AGGACCAAAGATGCCTCAAC-3′; mIL6ST_dn\_\#85, 5′-TGAAGGAAGTTCGAGGAGACA-3′; mYAP1_up\_\#99, 5′-TTCCGATCCCTTTCTTAACAGT-3′; mYAP1_dn\_\#99, 5′-GAGGGATGCTGTAGCTGCTC-3′; mCtgf_up\_\#85, 5′-CTGCAGACTGGAGAAGCAGA-3′; mCtgf_dn\_\#85, 5′-GCTTGGCGATTTTAGGTGTC-3′; mCyr61_up\_\#70, 5′-CGTCACCCTTCTCCACTTG-3′; mCyr61_dn\_\#70, 5′-CACTTGGGTGCCTCCAGA-3′; mBIRC5_up\_\#71, 5′-CCCGATGACAACCCGATA-3′; mBIRC5_dn\_\#71, 5′-CATCTGCTTCTTGACAGTGAGG-3′; mcMyc_up\_\#77, 5′-CCTAGTGCTGCATGAGGAGA-3′; mcMyc_dn\_\#77, 5′-TCCACAGACACCACATCAATTT-3′; hEGF-R\_\#25_up, 5′-CAGAGTGATGTCTGGAGCTACG-3′; hEGF-R\_\#25_dn, 5′-GGGAGGCGTTCTCCTTTCT-3′; hErbB2_up\_\#16, 5′-GCCATGAGCAGTGTGCTG-3′; hErbB2_dn\_\#16, 5′-ACAGATGCCACTGTGGTTGA-3′; hErbB3_up\_\#25, 5′-CAATCCCCACACCAAGTATCA-3′; hErbB3_dn\_\#25, 5′-GATGTTTGATCCACCACAAAGTT-3′; hErbB4_up\_\#25, 5′-GCGAGACAAACCCAAACAAG-3′; hErbB4_dn\_\#25, 5′-CAATGCTTGAAGGTCTCCATT-3′; hBTC_up\_\#49, 5′-ACTGCATCAAAGGGAGATGC-3′; hBTC_dn\_\#49, 5′-TCTCACACCTTGCTCCAATG-3′; hEGF_up\_\#77, 5′-CGCAGGAAATGGGAATTCTA-3′; hEGF_dn\_\#77, 5′-CCATGATCACTGAGACACCAG-3′; hAREG_up\_\#38, 5′-CGGAGAATGCAAATATATAGAGCAC-3′; hAREG_dn\_\#38, 5′-CACCGAAATATTCTTGCTGACA-3′; hEREG_p\_\#13, 5′-AGGAGGATGGAGATGCTCTG-3′; hEREG_dn\_\#13, 5′-GAGGACTGCCTGTAGAAGATGG-3′; hTGFa_up\_\#38, 5′-CCCAGATTCCCACACTCAG-3′; hTGFa_up\_\#38, 5′-ACGTACCCAGAATGGCAGAC-3′; hNRG-2_up\_\#38, 5′-TGTGGTGGCCTACTGCAA-3′; hNRG-2_dn\_\#38, 5′-ACATGTTCTGCCGGAGGT-3′; hADAM17_up\_\#77, 5′-CGTTTTTCACAAAATTTCAAGGT-3′; hADAM17_dn\_\#77, 5′-CCCTAGAGTCAGGCTCACCA-3′; hADAM17_up\_\#53, 5′-GCCAGCAGAGAGATATATTAAAGACC-3′; and hADAM10_dn\_\#53, 5′-GGACCGTATTTATGGGGATAGTT-3′. Quantification of relative changes in gene expression pattern was determined with LightCycler 480 Software 1.5.0 (Roche Diagnostics). Relative mRNA levels were assessed by the 2^-ΔΔCt^ method. The ΔCt rates were calculated for each sample by normalization to the housekeeping gene GAPDH. Comparative real-time PCR results were performed in triplicate.

RNA-seq analysis {#s17}
----------------

Tumor tissue and surrounding unaffected tissue of Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice were prepared fresh. To isolate total RNA from animal tissue for RNA-seq, the RNeasy Mini kit including a QIAshredder column (Qiagen) was used according to the supplier's instructions. RNA-seq was performed using standard protocols. Individual strand-specific sequencing libraries were prepared with the TruSeq stranded mRNA kit (Illumina) from 500 ng total RNA. Libraries were sequenced on an Illumina HiSeq2500 (125-nt paired-end reads) as described ([@bib21]). Reads were processed and mapped using the Bioconductor package DeSeq2 ([@bib40]). Network analyses were conducted using String database ([@bib25]) with default settings without allowing white nodes and additional interactors, and visualized in Cytoscape 3.5.1 ([@bib67]), and transcription factor binding site analyses were performed using the database oPossum 3.0 ([@bib35]). Data have been submitted to the Gene Expression Omnibus Repository: GEO submission [GSE107759](GSE107759){#dblnkb95c4300-ec95-7d15-67e9-8b25337e1a71}.

Microbiome analysis {#s18}
-------------------

Total DNA was isolated from fecal pellets using DNeasy PowerSoil kit (Qiagen). 16S ribosomal RNA gene variable region V3--V4 was amplified using bacterial domain--specific barcoded primer pair 319F and 806R as described ([@bib21]). Equal proportions of amplified amplicons from each sample were mixed and sequenced on the Miseq platform (Illumina). Sequences were quality controlled per the recommended Mothur MiSeq standard procedure ([@bib33]). Quality-controlled sequences were binned in phylotypes (Mothur-curated GreenGenes database) and operational taxonomical units (OTUs with 95% similarity). Alpha diversity indices were calculated on microbial profiles based on OTUs and genus-level phylotypes. Beta diversity analysis (nonmetric multidimensional scaling) was performed using unweighted uniFrac distances (10,000 iterations) in Mothur. Paired 16S rRNA gene reads (fastq) have been submitted to the European Nucleotide Archive (accession no. [PRJEB23659](https://www.ebi.ac.uk/ena/data/search?query=PRJEB23659){#urilnk19ad34eb-20a2-910f-cf37-4a2430359bbe}).

Predicted functional analysis of microbiota {#s19}
-------------------------------------------

Predication of functional potential of microbial communities was performed by implementing PICRUSt ([@bib36]). In brief, 16S rRNA gene sequences were mapped against the Mothur-curated GreenGenes reference database (gg_13_8\_99). A rarefied shared phylotype file with equal numbers of sequences per sample was used to generate a biom file in Mothur. The resulting biom file was subjected to online PICRUSt galaxy terminal (<http://huttenhower.sph.harvard.edu/galaxy/>) to predict the metabolic potential. Phylotypes were first normalized for the predicated 16 S RNA gene copy number: KEGG pathway functions were predicted at level 3 with the use of KEGG Orthologues GreenGenes 13_5 database in PICRUSt. Predicted metagenomic profiles were analyzed in STAMP software ([@bib51]) to assess the significance of predicted functional differences in microbial communities in two groups. Statistical significance of differences was tested using White's nonparametric test with Benjamini--Hochberg false discovery rate correction.

ELISA {#s20}
-----

ELISA kits for mouse (DY989, R&D Systems) and human (DY262, R&D Systems) Amphiregulin were used according to the supplier's instructions.

Organoids {#s21}
---------

The isolated small intestine was opened longitudinally, washed with ice-cold PBS, and cut into small pieces ([@bib63]). Tissue pieces were washed with ice-cold PBS and incubated in 2 mM EDTA and 0.5 mM DTT in PBS on ice for 30 min. After removal of the EDTA/DTT buffer, tissue pieces were resuspended in PBS, shaken vigorously, and allowed to settle for 5 min. The supernatant including released crypts was passed through a 100-µm cell strainer to remove cell debris and centrifuged at 500 *g*. The sedimented crypts were resuspended in Matrigel (Basement Membrane Matrix Growth Factor Reduced; Corning) at a 1:2 ratio with Gibco Advanced DMEM/F12 containing 1× GlutaMAX and 50 U/ml penicillin/streptomycin, plated in 24-well plates with 50 µl Matrigel GFR drops per well plus 500 µl individual medium, and cultured in a 37°C incubator at 5% CO~2~ air content and 90% relative humidity. APC tumor medium for organoids from Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice contained 25 ng/ml Noggin (Peprotech), 40 ng/ml EGF (Peprotech), 1× B27 minus insulin (Gibco), 1× N2 (Gibco), 100 U/ml penicillin/streptomycin (Gibco), 1× GlutaMax (Gibco), 10 mM Hepes (Gibco), 1 mM *N*-acetyl-cysteine (Sigma-Aldrich), 50 µg/ml gentamycin (Gibco), and 50 µg/ml primocin (Invivogen) in Advanced DMEM/F12 medium (Gibco) and were added to the Matrigel. For passaging, the Matrigel-embedded organoids were mechanically disrupted by resuspending in Advanced DMEM/F12 medium (Gibco) and passing through a needle (21G), centrifuged at 500 *g*, and resuspended in fresh Matrigel at a 1:2 ratio with Gibco Advanced DMEM/F12 containing 1× GlutaMax and 50 U/ml penicillin/streptomycin. The culture medium was changed every second day, and organoids were passaged twice a week at a 1:5 ratio. Organoids were seeded in 24-well plates, inhibitors were added as indicated in APC tumor medium, and organoids were incubated at 37°C for 72 h. For ELISA analysis, organoid supernatants were harvested, centrifuged at 1,000 *g* for 5 min, transferred into a new tube, and stored at −20°C until use. Each well was microscopically evaluated and photographed with the Nikon AZ100 microscope and NIS-Elements D 4.12.01 software to assess the number and size of every organoid.

Organoid IHC {#s22}
------------

For whole-mount immunofluorescent analysis, APC^min/+^ and APC^min/+^::ADAM17^ex/ex^ intestinal organoids were grown in Matrigel spots in microclear CellStar 96-well plates (Greiner Bio One). Organoids were fixed with 3% PFA in PBS, permeabilized (PBS and 0.5% Triton X-100), quenched (PBS and 100 mM glycine), and blocked using serum-free protein block (X0909; Dako). Staining with primary antibodies was performed at 4°C overnight, followed by detection using AF488- or AF594-labeled secondary antibodies (Thermo Fisher Scientific). Images were acquired on an Olympus Fluoview 1000 confocal laser scanning microscope. The α-β-catenin antibody was used at 1:200, the α-Ki67 antibody at 1:200, the α-pEGF-R antibody at 1:100, the α-pSTAT3 antibody at 1:200, and the α-T (brachyury) antibody at 1:100.

Tissue microarrays {#s23}
------------------

Tissue microarrays containing samples of 402 consecutive patients with UICC stage II--III CRC ([@bib32]) were cut and stained. In brief, tissue samples originated from patients who underwent surgery for colorectal carcinoma with negative margins in 1993--2006 at the surgical Department of the University Hospital of Friedrich-Schiller-University (Jena, Germany). Survival of patients was monitored until death or at least for 10 yr. The procedure concerning patients' data protection was according to regulations of the Friedrich-Schiller University (Jena, Germany). The ethical criteria in the tissue arrays used for this study are met by irreversible anonymization. The study protocol was in accordance with the ethical guidelines of the Helsinki Declaration.

Histology {#s24}
---------

Intestine was dissected and stored in ice-cold PBS. The junction between stomach and duodenum and the junction between ileum and cecum were cut to obtain the whole small intestine. The junction between cecum and colon was cut to obtain small intestine, which was repeatedly flushed with ice-cold PBS and opened longitudinally. For macroscopic assessment of tumor numbers and distribution, the intestine was photographed and evaluated with the NIS-Elements D 4.12.01 software. The intestine was rolled up with forceps from cranial to caudal part ("Swiss roll") and prepared for sectioning ([@bib45]). For preparation of formalin-fixed paraffin-embedded (FFPE) tissue, the rolled tissue was fixed in 4% PFA overnight, washed in H~2~O for 24 h, dehydrated by ascending alcohol series, and incubated in xylene for paraffin-embedded sections. Intestinal tissue was sectioned with a microtome at 4-µm thickness and stained in Azan or H&E after deparaffinization.

Histological stainings of FFPE tissue were performed by standard protocol before slides were covered with Eukitt. For antigen unmasking in the form of heat-induced epitope retrieval, protocols were used depending on primary antibody datasheet. If necessary, endogenous peroxidase activity was quenched by short incubation of FFPE tissue slides in 3% hydrogen peroxide. For permeabilization, slides were incubated with 0.1% (vol/vol) Triton X-100 in 1× PBS for 5 min. Specimens were blocked in 100 µl serum-free protein block (Dako; Agilent Technologies). Primary antibodies were diluted as recommended in antibody dilution solution (Invitrogen; Thermo Fisher Scientific) and incubated at 4°C overnight. After washing in PBS, the fluorochrome-conjugated secondary antibody was added in the dark. Sections were washed again in PBS in the dark before being mounted in ProLong Gold antifade reagent with DAPI (Thermo Fisher Scientific). If the protein of interest was targeted by an HRP-labeled secondary antibody, a DAB-substrate solution (0.05% DAB, 0.015% H~2~O~2~, and 0.01 M PBS, pH 7.2) was used to visualize labeled proteins. FFPE tissue slides were covered with DAB-substrate solution and incubated at RT. Slides were rinsed in ddH~2~O, drained, and covered with mounting medium.

Tumor staging {#s25}
-------------

Tumor staging was performed by two board-certified pathologists in a blinded manner according to described recommendations ([@bib9]). Infiltration of inflammatory cells in dysplasias was scored according to the following scheme: 0 = no infiltration of inflammatory cells, 1 = mild infiltration, 2 = moderate infiltration, and 3 = severe infiltration.

Cell culture {#s26}
------------

Human CRC cells were cultured in Iscove's modified Dulbecco's medium (IMEM), supplemented with 10% (vol/vol) FCS, 1% (vol/vol) sodium pyruvate, and 50 U/ml penicillin/streptomycin in a 37°C incubator at 5% CO~2~ air content and 90% relative humidity. Adherent cells were washed with PBS, scraped off, and lysed in lysis buffer at 4°C for 4 h.

Laser microdissection {#s27}
---------------------

Mice were killed, and small intestines were removed and washed with ice-cold PBS. The small intestine was opened longitudinally, and Tissue-Tek O.C.T. compound was applied onto the tissue surface. The intestine was rolled into a Swiss roll and directly placed in a Tissue-Tek Cryomold (Sakura) with Tissue-Tek O.C.T. compound on dry ice in methylbutane until O.C.T. compound and tissue were completely frozen. Freshly prepared cryosections (12 µm) were placed on glass membrane slides and stained with Toluidine blue. A laser-coupled microscope was used to remove the tissue area of interest. The dissected tissue area was collected and directly lysed with a innuPREP RNA kit according to the manufacturer's instructions.

Statistics {#s28}
----------

Histological evaluation was done by using the Nikon AZ100 microscope and NIS-Elements D 4.12.01 software. Tumor staging was performed in a blinded fashion by board-certified pathologists. Significance was calculated by unpaired *t* test with Welch's correction test for the comparison of two means. Mann--Whitney *U* or Kruskal--Wallis tests were used to evaluate discontinuous observations. ANOVA was used to compare differences for multiple groups followed by Tukey's multiple comparison test or Bonferroni post hoc test. All tests were performed using GraphPad Prism 6 software. Statistical analyses of tissue microarray data were calculated with Fisher's exact test. The Kaplan--Meier method was used to calculate survival curves. Statistical differences in survival were assessed by log-rank test. For all analyses, statistical significance was defined as P \< 0.05.

Online supplemental material {#s29}
----------------------------

Fig. S1 shows EGF-R and ADAM17 expression data in colorectal carcinoma patients. Fig. S2 shows gene expression analysis of intestinal organoids from Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice. Fig. S3 shows the distribution of dysplasias in the intestine of Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice. Fig. S4 shows the infiltration of macrophages and T cells in the intestine of Apc^Min/+^ and Apc^Min/+^::ADAM17^ex/ex^ mice. Fig. S5 depicts alterations in the intestinal microbiome upon loss of ADAM17.
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